跳至主要内容
临床试验/NCT00132860
NCT00132860Unknown4 期

Antibiotic Treatment of Patients With Chronic Obstructive Lung Disease: A Prospective, Randomized, Double-Blind Placebo-Controlled Study of Intermittent, Prophylactic Antibiotic Treatment With Azithromycin

Odense University Hospital2 个研究点 分布在 1 个国家目标入组 800 人开始时间: 2001年5月最近更新:
适应症
相关药物

试验速览

阶段
4 期
入组人数
800
试验地点
2
主要终点
change in postbronchodilator FEV1

研究概览

简要总结

The purpose of the study is to investigate, in patients with moderate to severe chronic obstructive lung disease, whether intermittent antibiotic treatment leads to:

  • A slower rate of decline in forced expiratory volume in one second (FEV1);
  • A reduction in the frequency and severity of exacerbations;
  • Fewer hospital admissions for chronic obstructive pulmonary disease (COPD);
  • Lower mortality;
  • An improved quality of life as compared to a group of placebo treated patients.

详细描述

Study Population: Patients with moderate to severe chronic obstructive lung disease.

Trial Phase: IV

Study Design: Prospective, randomised, double-blind, placebo- controlled clinical trial.

Study Medicine: Azithromycin.

Drug Administration: Oral.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Single Group
主要目的
Treatment
盲法
Double

入排标准

年龄范围
50 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients above 50 years of age, with a current admission for exacerbation of COLD or at least one admission within the previous two years.
  • Current or ex-smoker
  • Postbronchodilator FEV1 < 60% in stable condition (> 4 weeks after hospitalisation)
  • < 300 ml bronchodilator reversibility in FEV1

排除标准

  • Patients with end-stage COLD, who are not expected to survive for 3 years (typically bedridden patients being dyspnoeic in rest).
  • Patients with known other respiratory tract infection, e.g. tuberculosis or aspergillosis, in whom the intervention is known to be inefficient.
  • Patients with pulmonary malignancy
  • Patients with other pulmonary diseases than COLD.
  • Patients with immunodeficiency. However, COLD patients treated with steroids can be included.
  • Patients with known hereditary disposition to lung infections such as alfa-1-antitrypsin deficiency, cystic fibrosis or primary ciliary dyskinesia.
  • Patients receiving longterm antibiotic treatment ( e.g. recurrent cystitis).
  • Patients with known allergy or intolerance to azithromycin
  • Pregnant or breastfeeding women
  • Manifest heart, liver or renal insufficiency
  • Patients that, for reasons not stated above, are unlikely to be able to participate in a study period of 3 years.

结局指标

主要结局

change in postbronchodilator FEV1

次要结局

  • number of hospital admissions and number of hospital days
  • mortality
  • quality of life
  • use of medication
  • prevalence of respiratory pathogens
  • prevalence of macrolide resistance
  • inflammatory parameters

研究者

申办方类型
Other

研究点 (2)

Loading locations...

相似试验